| 20/05 | ASTELLAS PHARMA : Confirms Unfavorable District Court Decision in LEXISCAN® 0.4mg/mL U.S. .. | PU |
| 27/04 | ASTELLAS PHARMA : Changes of Representative Director and Directors | PU |
| 27/04 | ASTELLAS PHARMA : Financial Results (FY2021) | PU |
| 27/04 | ASTELLAS PHARMA : Supplementary Documents (FY2021) | PU |
| 27/04 | ASTELLAS PHARMA : Presentation Material for Information Meeting (FY2021) | PU |
| 26/04 | Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovatio.. | AQ |
| 22/04 | ASTELLAS PHARMA : Notice Regarding Impairment Loss for Products under Development | PU |
| 14/04 | ASTELLAS PHARMA : European Commission Approves PADCEV (enfortumab vedotin) for Locally Adv.. | PU |
| 05/04 | WE PUBLISHED A NEW SUSTAINABILITY SE : “Developing a sustainable society by leveragi.. | PU |
| 01/04 | ASTELLAS PHARMA : We published a Drug Research page. | PU |
| 15/03 | ASTELLAS PHARMA : Initiatives for Gene Therapy（2,933KB） | PU |
| 14/03 | WE PUBLISHED A STORY : “Reinvigorating the immune system to find new ways to cure ca.. | PU |
| 14/03 | ASTELLAS PHARMA : Reinvigorating the immune system to find new ways to cure cancer | PU |
| 10/03 | ASTELLAS PHARMA : Meeting Script（8,030KB） | PU |
| 10/03 | ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancellation of T.. | PU |
| 09/03 | ASTELLAS PHARMA : Update on ukraine | PU |
| 09/03 | ASTELLAS PHARMA : Presentation Material for R&D Meeting | PU |
| 09/03 | ASTELLAS PHARMA : Initiatives for Gene Therapy（2,929KB） | PU |
| 09/03 | ASTELLAS PHARMA : Updated “R&D meeting” Section | PU |
| 07/03 | ASTELLAS PHARMA : Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolin.. | PU |
| 02/03 | WE PUBLISHED A STORY : “Astellas' VALUE powered by people—New Challenge of HR... | PU |
| 02/03 | ASTELLAS PHARMA : ' VALUE powered by people — New Challenge of HR | PU |
| 01/03 | ASTELLAS PHARMA : Meeting Script（4,467KB） | PU |
| 01/03 | ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares | PU |
| 01/03 | ASTELLAS PHARMA : and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortuma.. | PU |
| 01/03 | ASTELLAS PHARMA : Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent.. | PU |
| 28/02 | ASTELLAS PHARMA : Updated “Sustainability Meeting” Section | PU |
| 28/02 | ASTELLAS PHARMA : Aiming to Enhance the Sustainability of Society and Astellas' Corporate .. | PU |
| 28/02 | ASTELLAS PHARMA : Presentation Material for Sustainability Meeting | PU |
| 17/02 | ASTELLAS PHARMA : New research organization structure（1,245kb） | PU |
| 14/02 | Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Pa.. | BU |
| 08/02 | Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with L.. | AQ |
| 08/02 | ASTELLAS PHARMA : Announces Management Structure | PU |
| 04/02 | ASTELLAS PHARMA : Initiates Charitable Donations to Support Four Organizations Focused on .. | PU |
| 02/02 | ASTELLAS PHARMA : Announces Acquisition of Own Shares and Cancellation of Treasury Stock | PU |
| 02/02 | ASTELLAS PHARMA : Financial Results (Q3/FY2021) | PU |
| 02/02 | ASTELLAS PHARMA : Presentation Material for Information Meeting (Q3/FY2021) | PU |
| 02/02 | ASTELLAS PHARMA : Supplementary Documents (Q3/FY2021) | PU |
| 24/01 | ASTELLAS PHARMA : Meeting Script（3,989KB） | PU |
| 21/01 | ASTELLAS PHARMA : We posted the presentation material for media briefing on Digital Transf.. | PU |
| 21/01 | ASTELLAS PHARMA : Digital Transformation of Astellas Pharma（3,351KB） | PU |
| 10/01 | Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t.. | AQ |
| 06/01 | Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration .. | AQ |
| 2021 | ASTELLAS PHARMA : and Seagen Receive Positive CHMP Opinion for PADCEV (enfortumab vedotin).. | PU |
| 2021 | Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin.. | BU |
| 2021 | ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo.. | PU |
| 2021 | Guard Therapeutics appoints Michael Reusch as Chief Medical Officer | AQ |
| 2021 | Astellas and MBC BioLabs Announce Future Innovator Prize Winners, Helping Biotech Start.. | AQ |
| 2021 | ASTELLAS PHARMA : Changes its Corporate Website Structure | PU |
| 2021 | Astellas Applied for Selection of 'Prime Market' segment of the Tokyo Stock Exchange | AQ |
| 2021 | ASTELLAS PHARMA : New Research Organization Structure | PU |
| 2021 | ASTELLAS PHARMA : Presentation Material for R&D Meeting | PU |
| 2021 | ASTELLAS PHARMA : Corporate Governance Report | PU |
| 2021 | ASTELLAS PHARMA : Applied for Selection of “Prime Market”segment of the Tokyo .. | PU |
| 2021 | ASTELLAS PHARMA : Applied for Selection of “Prime Market” segment of the Tokyo.. | PU |
| 2021 | ASTELLAS PHARMA : Corporate Covernance Report | PU |
| 2021 | Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia.. | AQ |
| 2021 | ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd.. | PU |
| 2021 | WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo.. | PU |
| 2021 | ASTELLAS PHARMA : Patient centricity at Astellas—all about action | PU |
| 2021 | ASTELLAS PHARMA : Annual Report 2021 is now available. | PU |
| 2021 | ASTELLAS PHARMA : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive.. | PU |
| 2021 | ASTELLAS PHARMA : ' Efforts Against the Spread of the Coronavirus Disease (COVID-19) | PU |
| 2021 | ASTELLAS PHARMA : and Pantherna Enter into Technology Evaluation Agreement for Research of.. | PU |
| 2021 | PLAUSIBILITY AND UNDUE BURDEN : A New Look Insufficiency After FibroGen v Akebia | AQ |
| 2021 | Earnings call script | PU |
| 2021 | Financial Results (Q2/FY2021) | PU |
| 2021 | Supplementary Documents (Q2/FY2021) | PU |
| 2021 | Presentation Material for Information Meeting (Q2/FY2021) | PU |
| 2021 | ASTELLAS PHARMA : We published our corporate brand movie on the VISION section. | PU |
| 2021 | ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”.. | PU |
| 2021 | Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo.. | AQ |
| 2021 | ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV.. | PU |
| 2021 | ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini.. | BU |
| 2021 | ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for .. | PU |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
